Jeremie Calais, MD, PhD

Jeremie Calais, MD, PhD

Associate Professor, Department of Molecular and Medical Pharmacology

Languages

English

Education

Fellowships

Nuclear Cardiology, Hospital Xavier Bichat, University of Paris, 2016
Oncology Imaging, University of Rouen School of Medicine, 2015

Degrees

PhD, University Paris-Saclay, Paris, France, 2023
MSc, University of Paris-Sud Saclay, Paris, France, 2017
MD, Faculty of Medicine Xavier Bichat, University of Paris, 2010

Residency

Nuclear Medicine, University of Rouen School of Medicine, 2014

Contact Information

Scientific Interests

Dr. Jeremie Calais' work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches. He uses Positron Emission Tomography/Computed Tomography (PET/CT) imaging for cancer phenotyping, radiation therapy planning and therapy response assessment. He leads the clinical theranostics research program at UCLA that combines radionuclide therapy and imaging.

Highlighted Publications

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler KA, Chu FI, King CR, Steinberg ML, Rausher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. (68)Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018 Feb;59(2):230-237. PMID: 29123013.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):856-863. PMID: 30920593

Calais J, Ceci F, Eiber M, Hope T, Hofman M, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan A, Rettig M, Reiter R, Fendler W, Czernin J. 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT in patients with biochemical recurrence after prostatectomy at PSA levels of ≤ 2.0ng/ml: a prospective single-center, single-arm, comparative imaging trial. Lancet Oncol. 2019 Sep; 20: 1286–94 PMID: 31375469

Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 Jul 8:S1470-2045(21)00274-6. Online ahead of print. PMID: 34246328

Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Sep 16:e213771. doi: 10.1001/jamaoncol.2021.3771. Online ahead of print. PMID: 34529005